Egalet Corporation has announced that the FDA has approved Arymo ER (morphine sulfate) extended-release (ER) tablets C-II for the management...
Endo International plc continues to believe in the safety, efficacy, and favorable benefit-risk profile of Opana ER (oxymorphone hydrochloride extended...
Osmotica Pharmaceutical announced that the FDA has approved Osmolex ER (amantadine HCl extended release), for the treatment of Parkinson's disease...
Egalet Corporation announced that the FDA has accepted the new drug application (NDA) for Arymo ER (morphine sulfate) extended-release tablets....
The FDA has on 3 April 2013 approved a New Drug Application (NDA) for Karbinal ER (carbinoxamine maleate) Extended-release Oral...
Remoxy ER has a thick, sticky, high-viscosity capsule formulation designed to deter unapproved routes of drug administration, such as injection,...
Trevi Therapeutics announced statistically significant results from its oral Nalbuphine ER Phase II/III trial for the treatment of moderate to...
The FDA has approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets) from Purdue Pharma, an extended-release/long-acting (ER/LA) opioid...
The FDA has requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market....
Teva Pharmaceutical has announced the FDA approved Vantrela ER (hydrocodone bitartrate) extended-release tablets [CII] formulated with Teva’s proprietary abuse deterrence...